Amgen (AMGN) Total Current Liabilities (2009 - 2026)

Amgen has reported Total Current Liabilities for 18 years, with the latest figure at $25.5 billion in Q2 2026.

• On a quarterly basis, Total Current Liabilities rose 24.55% year-over-year to $25.5 billion in Q2 2026; TTM through Jun 2026 was $25.5 billion, a 24.55% increase from a year earlier, with the FY2025 full-year figure at $25.5 billion, up 10.35% from the prior year.
• Total Current Liabilities was $25.5 billion for Q2 2026 at Amgen, up from $25.0 billion in the prior quarter.
• The five-year high for Total Current Liabilities was $25.5 billion in Q2 2026, with the low at $12.6 billion in Q2 2022.
• Average Total Current Liabilities over 5 years is $19.3 billion, with a median of $20.0 billion recorded in 2024.
• The sharpest annual moves came in 2022 and 2024: Total Current Liabilities retreated 13.49% in 2022, then soared 38.68% in 2024.
• Over 5 years, Total Current Liabilities stood at $15.7 billion in 2022, then gained by 17.24% to $18.4 billion in 2023, then rose by 25.59% to $23.1 billion in 2024, then increased by 10.35% to $25.5 billion in 2025, then advanced by 0.05% to $25.5 billion in 2026.
• The last three Total Current Liabilities figures came in at $25.5 billion (Q2 2026), $25.0 billion (Q1 2026), and $25.5 billion (Q4 2025), per Business Quant data.